-
公开(公告)号:US11472874B2
公开(公告)日:2022-10-18
申请号:US16965676
申请日:2019-01-31
Applicant: Alector LLC
Inventor: Philip Kong , Herve Rhinn , Tina Schwabe , Angie Yee , Ilaria Tassi , Muhammad Abbas Alhawagri , Arnon Rosenthal
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US11470827B2
公开(公告)日:2022-10-18
申请号:US16218299
申请日:2018-12-12
Applicant: Alector LLC
Inventor: Ilaria Tassi , Asa Abeliovich , Seung-Joo Lee , Arnon Rosenthal , Tina Schwabe
IPC: A01K67/027 , C07H21/04 , C07K14/705 , A61K49/00
Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from TREM1, TREML1, TREM2, TREML2, and TREML4, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human TREM immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human TREM repertoire.
-
公开(公告)号:US11440957B2
公开(公告)日:2022-09-13
申请号:US16959081
申请日:2018-12-21
Applicant: ALECTOR LLC
Inventor: Arnon Rosenthal , Eric Brown , Tina Schwabe , Angie Yee , Herve Rhinn
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US11254743B2
公开(公告)日:2022-02-22
申请号:US16869315
申请日:2020-05-07
Applicant: ALECTOR LLC
Inventor: Patricia Culp , Helen Lam , Arnon Rosenthal , Seung-Joo Lee , Nels P. Nielson , Robert Pejchal
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US11174313B2
公开(公告)日:2021-11-16
申请号:US15735946
申请日:2016-06-11
Applicant: ALECTOR LLC
Inventor: Arnon Rosenthal , Kate Monroe , Francesca Avogadri-Connors
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US11136390B2
公开(公告)日:2021-10-05
申请号:US15735947
申请日:2016-06-11
Applicant: ALECTOR LLC
Inventor: Kate Monroe , Helen Lam , Francesca Avogadri-Connors , Seung-Joo Lee , William Monteith , Herve Rhinn , Arnon Rosenthal
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US10308718B2
公开(公告)日:2019-06-04
申请号:US15867609
申请日:2018-01-10
Applicant: ALECTOR LLC
Inventor: Arnon Rosenthal , Tina Schwabe , Michael Kurnellas , Robert Pejchal , Anthony B. Cooper
IPC: C07K16/28 , A61K31/7088
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20190040131A1
公开(公告)日:2019-02-07
申请号:US16054840
申请日:2018-08-03
Applicant: ALECTOR LLC
Inventor: Patricia Culp , Helen Lam , Arnon Rosenthal , Seung-Joo Lee , Nels P. Nielson , Robert Pejchal
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US12297277B2
公开(公告)日:2025-05-13
申请号:US17836707
申请日:2022-06-09
Applicant: Alector LLC
Inventor: Tina Schwabe , Michael Kurnellas , Arnon Rosenthal , Robert Pejchal , Anthony B. Cooper
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20240270866A1
公开(公告)日:2024-08-15
申请号:US18423604
申请日:2024-01-26
Applicant: Alector LLC
Inventor: Andrew Pincetic , Arnon Rosenthal
CPC classification number: C07K16/2896 , A61P25/28 , G01N33/6854 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/56 , C07K2317/92
Abstract: The present disclosure provides antibodies and antibody fragments that bind to human SIRPA. In some embodiments, the antibodies are SIRPA agonists. The antibodies and antibody fragments disclosed herein may be used for the treatment and/or diagnosis of diseases, disorders, and conditions associated with reduced SIRPA activity.
-
-
-
-
-
-
-
-
-